Quadramet

Quadramet

Quadramet is a therapeutic drug that contains radioactive samarium-153 and a tetraphosphonate chelator called ethylenediaminetetramethylenephosphonic acid (EDTMP). It is used for pain palliation and to kill cancer cells in the treatment of lung cancer, prostate cancer, breast cancer, and osteosarcoma.From: Handbook of Nuclear Medicine and Molecular Imaging for Physicists [2022], A High-Throughput Hot Surface Ion Source for Electromagnetic Radioisotope Separation [2023], Hazardous Chemicals [2019], Phosphorus [2019]

Radiopharmaceuticals for Radionuclide Therapy

View Chapter

Purchase Book

Published in Michael Ljungberg, Handbook of Nuclear Medicine and Molecular Imaging for Physicists, 2022

Meltem Ocak, Emre Demirci, Jessie R. Nedrow, Rebecca Krimins

Quadramet is a therapeutic agent consisting of radioactive samarium and a tetraphosphonate chelator, ethylenediaminetetramethylenephosphonic acid (EDTMP). In 1998, a team from South Africa published results from nine individual dogs with bone tumours that were treated with Sm-153-EDTMP [65]. This therapy has subsequently been evaluated in dogs with metastatic bone lesions including osteosarcoma [66, 67].

A High-Throughput Hot Surface Ion Source for Electromagnetic Radioisotope Separation

View Article

Journal Information

Published in Nuclear Science and Engineering, 2023

Peter Norgard, Bradley D. Jeffries, Barry Higgins, John M. Gahl, J. David Robertson

The initial therapeutic radioisotope of focus is 153Sm, a beta-emitting radionuclide presently used for pain palliation in the FDA-approved drug QUADRAMET®. There is compelling interest in using high-specific-activity 153Sm as a possible treatment for bone cancer. The production of 153Sm at MURR involves thermal and epithermal neutron capture reactions of 99% enriched 152Sm targets (thermal neutron capture and resonance integral cross sections are 205 and 3038 b, respectively).1 Following reactor irradiation, the specific activity of the target is approximately 2.2 Ci/mg. By comparison, the theoretical specific activity following electromagnetic isotope separation is approximately 439 Ci/mg. While this enhancement to the specific activity involves some additional costs in production, it is of course justified given the potential gain in the effectiveness of 153Sm.

Explore chapters and articles related to this topic

Radiopharmaceuticals for Radionuclide Therapy

A High-Throughput Hot Surface Ion Source for Electromagnetic Radioisotope Separation